召回的正压通气设备与阻塞性肺疾病关联的省级研究
该回顾性纵向研究基于加拿大安大略省健康行政数据库,纳入2012-2018年新使用正压通气(PAP)的成人,比较召回与非召回设备制造商与阻塞性肺疾病(OLD)发生和进展的关系。中位随访超过7年,加权分析未发现召回设备与OLD发生或进展独立相关,但探索性分析提示早期COPD风险及后期住院就诊的轻微增加值得进一步研究。
要点
- 召回PAP设备与OLD发生或进展无独立关联。
- 探索性分析见2年内COPD风险轻度增加(csHR 1.15)。
- 6-10年后COPD住院就诊风险增加(csHR 1.37)。
核心结论
- 调整后,召回设备与其他制造商设备相比未独立增加OLD发生或进展风险。
- 早期COPD发病率增加和后期住院就诊影响需进一步研究。
研究设计与样本
- 回顾性纵向研究,使用加拿大安大略省健康行政数据库。
- 纳入2012-2018年新使用PAP的成人,随访至死亡或2023年3月。
- 共248,358人,中位随访超过7年;无OLD者178,390人,有OLD者69,968人。
- 采用逆概率加权平衡基线特征,计算加权病因特异性风险比(csHR)。
主要发现
- 无OLD者中,召回设备与COPD风险无显著差异(csHR 1.05,95%CI 0.97-1.15)。
- 无OLD者中,召回设备与哮喘风险无显著差异(csHR 1.08,95%CI 0.91-1.28)。
- 有OLD者中,次要结局无显著差异。
- 探索性分析:2年内COPD风险轻度增加(csHR 1.15,95%CI 1.00-1.31)。
- 探索性分析:PAP索赔后6-10年COPD住院就诊风险增加(csHR 1.37,95%CI 1.02-1.86)。
临床怎么用
- 对于使用召回PAP设备的患者,无需因OLD风险而常规改变管理策略。
- 可关注早期COPD发生及远期住院就诊风险,个体化随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited real-world data exist on the health impacts of the Philips Respironics recall for positive airway pressure (PAP) devices. RESEARCH QUESTION: What is the relationship between PAP device manufacturer and obstructive lung disease (OLD) development and progression? STUDY DESIGN AND METHODS: A retrospective longitudinal study was conducted by using Ontario health administrative databases (Canada) on all new adult PAP users (2012-2018) with or without OLD. Individuals were followed up from PAP claim date to death or March 2023. Outcomes included: (1) incident asthma/COPD (primary) and (2) inpatient/outpatient visits for asthma/COPD (secondary). Inverse probability weighting was used to balance baseline characteristics between individuals on recalled vs nonrecalled PAP devices, and weighted cause-specific hazard ratios (csHRs) were calculated. RESULTS: Among 248,358 individuals (median follow-up > 7 years), 178,390 had no OLD (44,244 [24.8%] claimed recalled devices), and 69,968 had OLD (18,409 [26.3%] claimed recalled devices). In individuals without OLD, weighted analyses showed no significant difference in incident COPD or asthma risk between groups: csHR of 1.05 (95% CI, 0.97-1.15) for COPD and 1.08 (95% CI, 0.91-1.28) for asthma. No significant difference was observed for secondary outcomes in individuals with OLD. Exploratory analyses revealed modest increases in COPD risk within 2 years (csHR, 1.15; 95% CI, 1.00-1.31) and inpatient COPD visits 6 to 10 years following the PAP claim (csHR, 1.37; 95% CI, 1.02-1.86). INTERPRETATION: In this real-world population study, compared with other manufacturers, recalled devices were not independently associated with OLD development or progression following adjustment. However, early increases in COPD incidence and late effects on inpatient visits warrant further investigation.
引用
- Kendzerska T, Talarico R, Povitz M, et al. Association Between a Recalled Positive Airway Pressure Device and Obstructive Lung Disease: A Province-Based Study. Chest. 2025. PMID: 40383186. doi:10.1016/j.chest.2025.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。